Strategic Growth Pillars: The leadership detailed a three-pillar roadmap: (1) A $1 million R&D investment to pioneer AI therapies addressing unmet needs; (2) A targeted $5–10 million biotech acquisition by July 2027 to broaden the pipeline; and (3) Uplisting to OTCQB by Q1 2026 and NASDAQ thereafter to boost liquidity and investor access. Unwavering Management Alignment: The team emphasized their $350,000 personal investment and salary deferral until reaching a $50 million valuation, aligning incentives wit ...

SEATTLE, July 28, 2025 (GLOBE NEWSWIRE) -- Fifty 1 Labs, Inc. (OTC: FITY), a leader in AI-powered health and wellness solutions, today announced it will host a virtual shareholder teleconference on Monday, July 28, 2025, at 12:00 PM EST. The event will be broadcast on X (formerly Twitter), featuring Nobel Peace Prize recipient Dr. James Orbinski, who accepted the 1999 Nobel Peace Prize on behalf of Médecins Sans Frontières (Doctors Without Borders) for the organization's groundbreaking humanitarian medical ...

Core Insights - Fifty1 AI Labs, LLC has successfully completed the REVIVE Adaptive Platform Trial, the largest Long COVID study to date, addressing a health crisis affecting approximately 400 million people globally and 15% of COVID-19 survivors, with an economic burden exceeding USD 1 trillion annually [1][2] - The trial demonstrates a clear treatment benefit for Long COVID, aligning with Fifty 1 Labs, Inc.'s vision to revolutionize healthcare through AI-driven drug repurposing and functional medicine, targeting the $5.68 trillion biotech market [2][3] - The company aims to achieve a $50 million valuation and lead the $320.6 billion functional medicine market, enhancing investor confidence and positioning for uplisting to OTCQB by Q1 2026 and NASDAQ in the coming years [2][7] Company Achievements - The REVIVE Trial enrolled over 600 participants, achieving the fastest recruitment for a study of its kind, showcasing operational excellence and strategic partnerships with leading institutions [3][4] - Fifty1 AI Labs' proprietary AI platform, supported by a $1 million R&D investment, optimizes drug candidate selection and accelerates clinical research efficiency, setting a new standard in the industry [4][5] - The findings from the REVIVE Trial are expected to establish a foundation for polypharmacy-based treatment regimens, unlocking significant opportunities for intellectual property development and potential annual revenue in the billions [5][6] Strategic Initiatives - The company is pursuing regulatory pathways to bring novel therapies to market and establishing R&D hubs in Vancouver, alongside strategic partnerships with pharmaceutical leaders [7] - Upcoming initiatives include the launch of a minimum viable product website by July 24, 2025, and a fully interactive website by July 31, 2025, aimed at enhancing investor engagement [7] - A virtual shareholder teleconference is scheduled for July 28, 2025, to provide insights into the company's transformative vision and progress toward uplisting [7]